5 Trends Shaping CDMO Hiring Right Now

The contract development and manufacturing sector is growing fast, and the talent market is shifting to match. Here's what's driving hiring decisions across CDMOs in 2025.

‍

TREND One

The race for GMP-experienced talent is intensifying

Good Manufacturing Practice expertise has always mattered in CDMO hiring, but competition for it has reached a different level. As more biologics, cell therapies, and advanced drug products move into commercial-scale manufacturing, the pool of candidates with hands-on GMP experience hasn't kept pace with demand.

CDMOs are now competing not just with each other but with large pharma companies that are bringing more manufacturing in-house. The result is that candidates with GMP batch record experience, process validation exposure, or quality systems ownership are fielding multiple approaches at once. Hiring managers who move slowly are losing out and the structural reasons why are worth understanding in more detail.

"We're regularly seeing candidates withdraw from processes because a faster-moving organisation made an offer before the first interview was even confirmed."

— Vector Talent, Hiring Insight

‍

TREND Two

Cell and gene therapy capabilities are reshaping job specs

The number of CDMOs expanding into cell and gene therapy (CGT) manufacturing has grown considerably over the past two years, a shift that was a dominant theme at DCAT Week 2026 and shows no sign of slowing. Viral vector production, plasmid manufacturing, and aseptic fill-finish for gene therapy products require skills that didn't feature in most CDMO job descriptions five years ago.

What this means practically is that traditional small-molecule manufacturing experience no longer translates as directly as it once did. Organisations building out CGT capacity are writing new competency frameworks from scratch, and in many cases looking for people from academic research settings or early-stage biotechs who've worked closer to the science.

‍

Trend THREE

Leadership hiring has shifted from technical to commercial-technical hybrids

There's been a clear shift at director level and above towards candidates who can combine deep technical knowledge with business development sensibility. CDMOs aren't just manufacturing partners anymore; they're expected to consult, advise, and co-develop with their clients. That puts pressure on senior hires to bring more than operational expertise.

Business development directors with manufacturing science backgrounds are particularly sought after. So are technical operations leaders who understand client relationship management and can contribute to proposal writing, pricing conversations, and contract negotiations. The boundaries between commercial and technical roles are blurring. It's a pattern we explored in depth when looking at the emerging CRDMO leadership gap.

‍

Trend FOUR

Geographic concentration is creating localised talent shortages

CDMO capacity has expanded in specific clusters, particularly around the UK's golden triangle, Ireland's pharmaceutical corridor, and key hubs in Germany, Switzerland, and the US East Coast. This concentration creates a paradox: nationally there may be enough qualified professionals, but locally there aren't enough of them within commutable distance of a given facility.

Remote-friendly arrangements have helped in some functional areas, but manufacturing roles are inherently site-based. This has pushed some CDMOs towards relocation packages that were unheard of for mid-level roles three years ago, and has made proximity to candidate-rich locations a genuine factor in site selection conversations.

In several UK regions, the same core pool of process scientists and quality professionals is being recruited by four or five competing organisations simultaneously.

‍

Trend FIVE

Retention is now as strategic as recruitment

CDMOs have historically operated with relatively high turnover in technical operations roles, treating it as an accepted cost. That tolerance is changing. In a tight talent market, losing a process development scientist or a QA manager means an extended period of reduced capacity, plus significant recruitment cost in a competitive landscape.

Organisations that are getting this right are investing in structured career pathways, skills development programmes, and in some cases expanding responsibilities earlier than they might have previously. The companies retaining their best people tend to be the ones where progression feels real, not theoretical. That's becoming a tangible competitive advantage when it comes to attracting new hires too.

‍

What this means for your hiring strategy

The common thread across all five of these trends is speed and specificity. The CDMOs succeeding in this market aren't necessarily the biggest or the best-funded; they're the ones with clear profiles for the roles they need to fill, streamlined hiring processes, and a realistic view of what they're competing against.

If your organisation is planning headcount growth in the next 12 months, the earlier you engage with the talent market, the better positioned you'll be. At Vector Talent, we work exclusively within the life sciences and CDMO space, which means we understand these pressures first-hand and can help you move with the pace the market demands.